What is Fasenra and what is it used for?
Fasenra (benralizumab) is an add-on maintenance treatment for severe eosinophilic asthma in adult and pediatric patients aged 6 years and older [1]. It targets the alpha receptor on eosinophils, a type of white blood cell, reducing their numbers and thereby improving asthma control [2].
When does Fasenra's patent expire?
Fasenra has multiple patents protecting it. According to DrugPatentWatch.com, the earliest patent expiration date for Fasenra is in 2027 [3]. However, subsequent patents extend its protection further.
What are the different types of patents on Fasenra?
Fasenra is protected by various patents covering different aspects of the drug, including its formulation, method of use, and manufacturing processes [3]. These layered patents are common for biologic drugs and contribute to their extended market exclusivity.
How long is Fasenra protected by patents?
The patent protection for Fasenra extends through the 2030s, with the latest patent expiration listed as 2039 [3]. This means that generic or biosimilar versions are unlikely to enter the market until after this date.
Who manufactures Fasenra?
Fasenra is manufactured by AstraZeneca [1].
What are the potential risks or side effects associated with Fasenra?
The most common side effects reported for Fasenra include headache, injection site reactions, and pharyngitis [1]. Serious allergic reactions, including anaphylaxis, can occur [1].
How does Fasenra compare to other asthma medications?
Fasenra is a biologic therapy targeting a specific pathway in severe eosinophilic asthma, distinguishing it from traditional inhalers or oral corticosteroids that may be used for less severe asthma [1, 2]. Its use is generally reserved for patients whose asthma is not adequately controlled with current therapies [1].